Evidence of immunosuppression in the maintenance of renal transplantation;Evidencias en la inmunosupresión de mantenimiento en el trasplante renal

Nefrologia

Volumn 25, Issue 4, 2005, Pages 369-380

  Hernández, Domingo ^a,b   Gonzalez Posada J M ^a  

^a HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^b NONE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CALCINEURIN; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN;

ADULT; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG COMBINATION; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MALE; META ANALYSIS; METHODOLOGY; MORTALITY; MULTICENTER STUDY; REVIEW; RISK FACTOR;

ADULT; AZATHIOPRINE; CALCINEURIN; CLINICAL TRIALS; DRUG THERAPY, COMBINATION; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; META-ANALYSIS; MULTICENTER STUDIES; MYCOPHENOLIC ACID; RISK FACTORS; SIROLIMUS;

EID: 27744512787     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (104)

1. Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi AB: Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 346: 580-590, 2002.
2. Meier-Kriesche HU, Schold JD, Kaplan B: Long-term renal allograft survival: have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant 4: 1289-1295, 2004.
3. Boots JM, Christiaans MH, Van Hooff JP: Effect of immunosuppressive agents on long-term survival of renal transplant recipients: focus on the cardiovascular risk. Drugs 64: 2047-2073, 2004.
4. Kasiske BL, Chakkera HA, Louis TA, Ma JZ: A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 11: 1910-1917, 2000.
5. Pascual J, Quereda C, Zamora J, Hernández D, Spanish Group for Evidence-Based Medicine in Renal Transplantation: Steroid withdrawal in renal transplant patients on triple therapy with a calcineurin inhibitor and mycophenolate mofetil: a meta-analysis of randomized, controlled trials. Transplantation 78: 1548-1556, 2004.
6. Vincenti F, Monaco A, Grinyo J, Kinkhabwala M, Roza A: Multicenter randomized prospective trial of steroid withdrawal in renal transplant recipients receiving basiliximab, cyclosporine microemulsion and mycophenolate mofetil. Am J Transplant 3: 306-311, 2003.
7. Borrows R, Loucaidou M, Van Tromp J, Cairns T, Griffith M, Hakim N, McLean A, Palmer A, Papalois V, Taube D: Steroid sparing with tacrolimus and mycophenolate mofetil in renal transplantation. Am J Transplant 4: 1845-1851, 2004.
8. Vanrenterghem Y, Van Hooff JP, Squifflet JP, Salmela K, Rigotti P, Jindal RM, Pascual J, Ekberg H, Sicilia LS, Boletis JN, Grinyo JM, Rodríguez MA; European Tacrolimus/MMF Renal Transplantation Study Group: Minimization of immunosuppressive therapy after renal transplantation: results of a randomized controlled trial. Am J Transplant 5: 87-95, 2005.
9. Woodle ES, Vincenti F, Lorber MI, Gritsch HA, Hricik D, Washburn K, Matas AJ, Gallichio M, Neylan J: A multicenter pilot study of early (4-day) steroid cessation in renal transplant recipients under simulect, tacrolimus and sirolimus. Am J Transplant 5: 157-166, 2005.
10. Lemieux I, Houde I, Pascot A, Lachance JG, Noel R, Radeau T, Despres JP, Bergeron J: Effects of prednisone withdrawal on the new metabolic triad in cyclosporine-treated kidney transplant patients. Kidney Int 62: 1839-1847, 2002.
11. Vanrenterghem Y, Lebranchu Y, Hene R, Oppenheimer F, Ekberg H: Double-blind comparison of two corticosteroid regimens plus mycophenolate mofetil and cyclosporine for prevention of acute renal allograft rejection. Transplantation 70: 1352-1359, 2000.
12. Opelz G, Dohler B: Cyclosporine and long-term kidney graft survival. Transplantation 72: 1267-73, 2001.
13. Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D: Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 342: 605-12, 2000.
14. Ojo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW, Arndorfer J, Christensen L, Merion RM: Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 349: 931-40, 2003.
15. Solez K, Vincenti F, Filo RS: Histopathologic findings from 2-year protocol biopsies from a US multicenter kidney transplant trial comparing tacrolimus versus cyclosporine: a report of the FK506 Kidney Transplant Study Group. Transplantation 66: 1736-40, 1998.
16. Marcen R, Pascual J, Teruel JL, Villafruela JJ, Rivera ME, Mampaso F, Burgos FJ, Ortuno J: Outcome of cadaveric renal transplant patients treated for 10 years with cyclosporine: is chronic allograft nephropathy the major cause of late graft loss? Transplantation 72: 57-62, 2001.
17. Gallagher MP, Hall B, Craig J, Berry G, Tiller DJ, Eris J; Australian Multicenter Trial of Cyclosporine Withdrawal Study Group and the ANZ Dialysis and Transplantation Registry: a randomized controlled trial of cyclosporine withdrawal in renal-transplant recipients: 15-year results. Transplantation 78: 1653-60, 2004.
18. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR: The natural history of chronic allograft nephropathy. N Engl J Med 349: 2326-33, 2003.
19. Vincenti F: Immunosuppression minimization: current and future trends in transplant immunosuppression. J Am Soc Nephrol 14: 1940-8, 2003.
20. Anjum S, Andany MA, McClean JC, Danielson B, Kasiske BL: Defining the risk of elective cyclosporine withdrawal in stable kidney transplant recipients. Am J Transplant 2: 179-85, 2002.
21. Grinyo JM, Cruzado JM, Millán O, Caldes A, Sabaté I, Gil-Vernet S, Serón D, Brunet M, Campistol JM, Torras J, Martorell J: Low-dose cyclosporine with mycophenolate mofetil induces similar calcineurin activity and cytokine inhibition as does standard-dose cyclosporine in stable renal allografts. Transplantation 78: 1400-3, 2004.
22. MacPhee IA, Bradley JA, Briggs JD, Junor BJ, MacPherson SG, McMillan MA, Rodger RS, Watson MA: Long-term outcome of a prospective randomized trial of conversion from cyclosporine to azathioprine treatment one year after renal transplantation. Transplantation 66: 1186-92, 1998.
23. Dubey D, Kumar A, Srivastava A, Mandhani A, Sharma AP, Gupta A, Sharma RK: Cyclosporin A withdrawal in live related renal transplantation: long-term results. Clin Transplant 15: 136-41, 2001.
24. Schnuelle P, Van der Heide JH, Tegzess A, Verburgh CA, Paul LC, Van der Woude FJ, De Fijter JW: Open randomized trial comparing early withdrawal of either cyclosporine or mycophenolate mofetil in stable renal transplant recipients initially treated with a triple drug regimen. J Am Soc Nephrol 13: 536-43, 2002.
25. Smak Gregoor PJ, De Sevaux RG, Ligtenberg G, Hoitsma AJ, Hene RJ, Weimar W, Hilbrands LB, van Gelder T: Withdrawal of cyclosporine or prednisone six months after kidney transplantation in patients on triple drug therapy: a randomized, prospective, multicenter study. J Am Soc Nephrol 13: 1365-73, 2002.
26. Abramowicz D, Manas D, Lao M, Vanrenterghem Y, Del Castillo D, Wijngaard P, Fung S; Cyclosporine Withdrawal Study Group: Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen in stable kidney transplant recipients: a randomized, controlled study. Transplantation 74: 1725-34, 2002.
27. Bakker RC, Hollander AA, Mallat MJ, Bruijn JA, Paul LC, De Fijter JW: Conversion from cyclosporine to azathioprine at three months reduces the incidence of chronic allograft nephropathy. Kidney Int 64: 1027-34, 2003.
28. Pascual M, Curtis J, Delmonico FL, Farrell ML, Williams WW Jr, Kalil R, Jones P, Cosimi AB, Tolkoff-Rubin N: A prospective, randomized clinical trial of cyclosporine reduction in stable patients greater than 12 months after renal transplantation. Transplantation 75: 1501-5, 2003.
29. Kuypers DR, Evenepoel P, Maes B, Coosemans W, Pirenne J, Vanrenterghem Y: The use of an anti-CD25 monoclonal antibody and mycophenolate mofetil enables the use of a low-dose tacrolimus and early withdrawal of steroids in renal transplant recipients. Clin Transplant 17: 234-41, 2003.
30. Baboolal K: A phase III prospective, randomized study to evaluate concentration-controlled sirolimus (rapamune) with cyclosporine dose minimization or elimination at six months in de novo renal allograft recipients. Transplantation 75: 1404-8, 2003.
31. Johnson RW, Kreis H, Oberbauer R, Brattstrom C, Claesson K, Eris J: Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 15; 72 (5): 777-86, 2001.
32. Gonwa TA, Hricik DE, Brinker K, Grinyo JM, Schena FP; Sirolimus Renal Function Study Group: Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination. Transplantation 74: 1560-7, 2002.
33. Oberbauer R, Kreis H, Johnson RW, Mota A, Claesson K, Ruiz JC, Wilczek H, Jamieson N, Henriques AC, Paczek L, Chapman J, Burke JT; Rapamune Maintenance Regimen Study Group: Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study. Transplantation 76: 364-70, 2003.
34. Kreis H, Oberbauer R, Campistol JM, Mathew T, Daloze P, Schena FP, Burke JT, Brault Y, Gioud-Paquet M, Scarola JA, Neylan JF; Rapamune Maintenance Regimen Trial: Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. J Am Soc Nephrol 15: 809-17, 2004.
35. Mota A, Arias M, Taskinen EI, Paavonen T, Brault Y, Legendre C, Claesson K, Castagneto M, Campistol JM, Hutchison B, Burke JT, Yilmaz S, Hayry P, Neylan JF; Rapamune Maintenance Regimen Trial: Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years. Am J Transplant 4: 953-61, 2004.
36. Ruiz JC, Campistol JM, Grinyo JM, Mota A, Prats D, Gutiérrez JA, Henriques AC, Pinto JR, García J, Morales JM, Gomez JM, Arias M: Early cyclosporine a withdrawal in kidney-transplant recipients receiving sirolimus prevents progression of chronic pathologic allograft lesions. Transplantation 78: 1312-8, 2004.
37. Oberbauer R, Segoloni G, Campistol JM, Kreis H, Mota A, Lawen J, Russ G, Grinyo JM, Stallone G, Hartmann A, Pinto JR, Chapman J, Burke JT, Brault Y, Neylan JF; Rapamune Maintenance Regimen Study Group: Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transpl Int 18: 22-8, 2005.
38. Hariharan S, McBride MA, Cherikh WS, Tolleris CB, Bresnahan BA, Johnson CP: Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int 62: 311-8, 2002.
39. Siddiqi N, McBride MA, Hariharan S: Similar risk profiles for post-transplant renal dysfunction and long-term graft failure: UNOS/OPTN database analysis. Kidney Int 65: 1906-13, 2004.
40. Kasiske BL, Andany MA, Hernández D, Silkensen J, Rabb H, McClean J, Roel JP, Danielson B: Comparing methods for monitoring serum creatinine to predict late renal allograft failure. Am J Kidney Dis 38: 1065-73, 2001.
41. Groth CG, Backman L, Morales JM, Calne R, Kreis H, Lang P, Touraine JL, Claesson K, Campistol JM, Durand D, Wramner L, Brattstrom C, Charpentier B: Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 67: 1036-42, 1999.
42. Kreis H, Cisterne JM, Land W, Wramner L, Squifflet JP, Abramowicz D, Campistol JM, Morales JM, Grinyo JM, Mourad G, Berthoux FC, Brattstrom C, Lebranchu Y, Vialtel P. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 69: 1252-60, 2000.
43. Tran HT, Acharya MK, McKay DB, Sayegh MH, Carpenter CB, Auchincloss H JR, Kirkman RL, Milford EL: Avoidance of cyclosporine in renal transplantation: effects of daclizumab, mycophenolate mofetil, and steroids. J Am Soc Nephrol 11: 1903-9, 2000.
44. Vincenti F, Ramos E, Brattstrom C, Cho S, Ekberg H, Grinyo J, Johnson R, Kuypers D, Stuart F, Khanna A, Navarro M, Nashan B: Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation 71: 1282-7, 2000.
45. Flechner SM, Goldfarb D, Modlin C, Feng J, Krishnamurthi V, Mastroianni B, Savas K, Cook DJ, Novick AC: Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 74: 1070-76, 2002.
46. Grinyo JM, Gil-Vernet S, Cruzado JM, Caldes A, Riera L, Serón D, Rama I, Torrás J: Calcineurin inhibitor-free immunosuppression based on antithymocyte globulin and mycophenolate mofetil in cadaveric kidney transplantation: results after 5 years. Transpl Int 16: 820-7, 2003.
47. Lo A, Egidi MF, Gaber LW, Amiri HS, Vera S, Nezakatgoo N, Gaber AO: Comparison of sirolimus-based calcineurin inhibitor-sparing and calcineurin inhibitor-free regimens in cadaveric renal transplantation. Transplantation 77: 1228-35, 2004.
48. Flechner SM, Kurian SM, Solez K, Cook DJ, Burke JT, Rollin H, Hammond JA, Whisenant T, Lanigan CM, Head SR, Salomon DR: De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. Am J Transplant 4: 1776-85, 2004.
49. Cole E, Maham N, Cardella C, Cattran D, Fenton S, Hamel J, O'Grady C, Smith R: Clinical benefits of neoral C2 monitoring in the long-term management of renal transplant recipients. Transplantation 75: 2086-90, 2003.
50. Di Paolo S, Teutonico A, Schena A, Infante B, Stallone G, Grandaliano G, Ditonno P, Battaglia M, Schena FP: Conversion to C2 monitoring of cyclosporine A exposure in maintenance kidney transplant recipients: results at 3 years. Am J Kidney Dis 44: 886-92, 2004.
51. Hardinger KL, Schnitzler MA, Koch MJ, Enkvetchakul D, Desai N, Jendrisak M, Lowell JA, Miller B, Shenoy S, Brennan DC: Cyclosporine minimization and cost reduction in renal transplant recipients receiving a C2-monitored, cyclosporine-based quadruple immunosuppressive regimen. Transplantation 78: 1198-203, 2004.
52. Vincenti F, Jensik SC, Filo RS, Miller J, Pirsch J: A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. Transplantation 73: 775-82, 2002.
53. rd, Rocher L, Scandling J, Sorensen J, Mulloy L, Light J, Corwin C, Danovitch G, Wachs M, Van Veldhuisen P, Leonhardt M, Fitzsimmons WE: Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years. Transplantation 75: 2048-53, 2003.
54. Pascual J, Segoloni G, González Molina M, Del Castillo D, Capdevila L, Arias M, García J, Ortuno J; Spanish-Italian Tacrolimus Study Group: Comparison between a two-drug regimen with tacrolimus and steroids and a triple one with azathioprine in kidney transplantation: results of a European trial with 3-year follow up. Transplant Proc 35: 1701-3, 2003.
55. Kaplan B, Schold JD, Meier-Kriesche HU: Long-term graft survival with neoral and tacrolimus: a paired kidney analysis. J Am Soc Nephrol 14: 2980-4, 2003.
56. Gill JS, Tonelli M, Mix CH, Johnson N, Pereira BJ: The effect of maintenance immunosuppression medication on the change in kidney allograft function. Kidney Int 65: 692-9, 2004.
57. Pascual J, Marcen R, Burgos FJ, Tenorio MT, Merino JL, Arambarri M, Villafruela JJ, Liano F, Mampaso F, Ortuno J: One-center comparison between primary immunosuppression based on neoral cyclosporine and tacrolimus for renal transplantation. Transplant Proc 34: 94-5, 2002.
58. Neu AM, Ho PL, Fine RN, Furth SL, Fivush BA: Tacrolimus vs cyclosporine A as primary immunosuppression in pediatric renal transplantation: a NAPRTCS study. Pediatr Transplant 7: 217-22, 2003.
59. Jurewicz WA: Tacrolimus versus cyclosporin immunosuppression: long-term outcome in renal transplantation. Nephrol Dial Transplant 18 (Supl. 1): i7-11, 2003.
60. Meier-Kriesche HU, Kaplan B: Cyclosporine microemulsion and tacrolimus are associated with decreased chronic allograft failure and improved long-term graft survival as compared with sandimmune. Am J Transplant 2: 100-4, 2002.
61. Irish W, Sherrill B, Brennan DC, Lowell J, Schnitzler M: Three-year posttransplant graft survival in renal-transplant patients with graft function at 6 months receiving tacrolimus or cyclosporine microemulsion within a triple-drug regimen. Transplantation 76: 1686-90, 2003.
62. Margreiter R; European Tacrolimus vs Ciclosporin Microemulsion Renal Transplantation Study Group: efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study. Lancet 359: 741-6, 2002.
63. Offermann G: Immunosuppression for long-term maintenance of renal allograft function. Drugs 64: 1325-38, 2004.
64. Khanna A, Plummer M, Bromberek C, Bresnahan B, Hariharan S: Expression of TGF-beta and fibrogenic genes in transplant recipients with tacrolimus and cyclosporine nephrotoxicity. Kidney Int 62: 2257-63, 2002.
65. McCune TR, Thacker LR II, Peters TG, Mulloy L, Rohr MS, Adams PA, Yium J, Light JA, Pruett T, Gaber AO, Selman SH, Jonsson J, Hayes JM, Wright FH Jr, Armata T, Blanton J, Burdick JF: Effects of tacrolimus on hyperlipidemia after successful renal transplantation: a Southeastern Organ Procurement Foundation multicenter clinical study. Transplantation 65: 87-92, 1998.
66. Ligtenberg G, Hene RJ, Blankestijn PJ, Koomans HA: Cardiovascular risk factors in renal transplant patients: cyclosporin A versus tacrolimus. J Am Soc Nephrol 12: 368-73, 2001.
67. Baid-Agrawal S, Delmonico FL, Tolkoff-Rubin NE, Farrell M, Williams WW, Shih V, Auchincloss H, Cosimi AB, Pascual M: Cardiovascular risk profile after conversion from cyclosporine A to tacrolimus in stable renal transplant recipients. Transplantation 77: 1199-202, 2004.
68. Artz MA, Boots JM, Ligtenberg G, Roodnat JI, Christiaans MH, Vos PF, Blom HJ, Sweep FC, Demacker PN, Hilbrands LB: Improved cardiovascular risk profile and renal function in renal transplant patients after randomized conversion from cyclosporine to tacrolimus. J Am Soc Nephrol 14: 1880-8, 2003.
69. Mas V, Alvarellos T, Giraudo C, Massari P, De Boccardo G: Intragraft messenger RNA expression of angiotensinogen: relationship with transforming growth factor beta-1 and chronic allograft nephropathy in kidney transplant patients. Transplantation 74: 718-21, 2002.
70. European Mycophenolate Mofetil Cooperative Study Group: Mycophenolate mofetil in renal transplantation: 3-year results from the placebo-controlled trial. Transplantation 68: 391-6, 1999.
71. US Renal Transplant Mycophenolate Mofetil Study Group: Mycophenolate mofetil in cadaveric renal transplantation. Am J Kidney Dis 34: 296-303, 1999.
72. Mathew TH: A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation: results at three years. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 65: 1450-4, 1998.
73. Ojo AO, Meier-Kriesche HU, Hanson JA, Leichtman AB, Cibrik D, Magee JC, Wolfe RA, Agodoa LY, Kaplan B: Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 69: 2405-9, 2000.
74. Meier-Kriesche HU, Steffen BJ, Hochberg AM, Gordon RD, Liebman MN, Morris JA, Kaplan B: Mycophenolate mofetil versus azathioprine therapy is associated with a significant protection against long-term renal allograft function deterioration. Transplantation 75: 1341-6, 2003.
75. Merville P, Berge F, Deminiere C, Morel D, Chong G, Durand D, Rostaing L, Mourad G, Potaux L: Lower incidence of chronic allograft nephropathy at 1 year post-transplantation in patients treated with mycophenolate mofetil. Am J Transplant 4: 1769-75, 2004.
76. Yang CW, Ahn HJ, Kim WY, Li C, Kim HW, Choi BS, Cha JH, Kim YS, Kim J, Bang BK: Cyclosporine withdrawal and mycophenolate mofetil treatment effects on the progression of chronic cyclosporine nephrotoxicity. Kidney Int 62: 20-30, 2002.
77. Jolicoeur EM, Qi S, Xu D, Dumont L, Daloze P, Chen H: Combination therapy of mycophenolate mofetil and rapamycin in prevention of chronic renal allograft rejection in the rat. Transplantation 75: 54-9, 2003.
78. Weir MR, Ward MT, Blahut SA, Klassen DK, Cangro CB, Bartlett ST, Fink JC: Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy. Kidney Int 59: 1567-73, 2001.
79. Ducloux D, Motte G, Billerey C, Bresson-Vautrin C, Vautrin P, Rebibou JM, Saint-Hillier Y, Chalopin JM: Cyclosporin withdrawal with concomitant conversion from azathioprine to mycophenolate mofetil in renal transplant recipients with chronic allograft nephropathy: a 2-year follow-up. Transpl Int 15: 387-92, 2002.
80. González Molina M, Serón D, García del Moral R, Carrera M, Sola E, Jesús Alférez M, Gómez Ullate P, Capdevila L, Gentil MA: Mycophenolate mofetil reduces deterioration of renal function in patients with chronic allograft nephropathy. A follow-up study by the Spanish Cooperative Study Group of Chronic Allograft Nephropathy. Transplantation 77: 215-20, 2004.
81. Kahan BD: Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Lancet 356:194-202, 2000.
82. Kahan BD, Julian BA, Pescovitz MD, Vanrenterghem Y, Neylan J: Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allografts: a phase II trial. Rapamune Study Group. Transplantation 68: 1526-32, 1999.
83. Halloran PF: Immunosuppressive drugs for kidney transplantation. N Engl J Med 351: 2715-29, 2004.
84. Ikonen TS, Gummert JF, Hayase M, Honda Y, Hausen B, Christians U, Berry GJ, Yock PG, Morris RE: Sirolimus (rapamycin) halts and reverses progression of allograft vascular disease in non-human primates. Transplantation 70: 969-75, 2000.
85. Shihab FS, Bennett WM, Yi H, Choi SO, Andoh TF: Sirolimus increases transforming growth factor-beta1 expression and potentiates chronic cyclosporine nephrotoxicity. Kidney Int 65: 1262-71, 2004.
86. Saunders RN, Bicknell GR, Nicholson ML: The impact of cyclosporine dose reduction with or without the addition of rapamycin on functional, molecular, and histological markers of chronic allograft nephropathy. Transplantation 75: 772-80, 2003.
87. Kaplan B, Schold J, Srinivas T, Womer K, Foley DP, Patton P, Howard R, Meier-Kriesche HU: Effect of sirolimus withdrawal in patients with deteriorating renal function. Am J Transplant 4: 1709-12, 2004.
88. Stallone G, Di Paolo S, Schena A, Infante B, Grandaliano G, Battaglia M, Gesualdo L, Schena FP: Early withdrawal of cyclosporine A improves 1-year kidney graft structure and function in sirolimus-treated patients. Transplantation 75: 998-1003, 2003.
89. Diekmann F, Budde K, Oppenheimer F, Fritsche L, Neumayer HH, Campistol JM: Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant 4: 1869-75, 2004.
90. Lutz J, Zou H, Liu S, Antus B, Heemann U: Apoptosis and treatment of chronic allograft nephropathy with everolimus. Transplantation 76: 508-15, 2003.
91. Nickeleit V, Klimkait T, Binet IF, Dalquen P, Del Zenero V, Thiel G, Mihatsch MJ, Hirsch HH: Testing for polyomavirus type BK DNA in plasma to identify renal-allograft recipients with viral nephropathy. N Engl J Med 342: 1309-15, 2000.
92. Hirsch HH, Knowles W, Dickenmann M, Passweg J, Klimkait T, Mihatsch MJ, Steiger J: Hirsch HH, Knowles W, Dickenmann M, Passweg J, Klimkait T, Mihatsch MJ, Steiger J. N Engl J Med 347: 488-96, 2002.
93. Nickeleit V, Hirsch HH, Zeiler M, Gudat F, Prince O, Thiel G, Mihatsch MJ: BK-virus nephropathy in renal transplantstubular necrosis, MHC-class II expression and rejection in a puzzling game. Nephrol Dial Transplant 15: 324-32, 2000.
94. Barri YM, Ahmad I, Ketel BL, Barone GW, Walker PD, Bonsib SM, Abul-Ezz SR: Polyoma viral infection in renal transplantation: the role of immunosuppressive therapy. Clin Transplant 15: 240-6, 2001.
95. Ramos E, Drachenberg CB, Papadimitriou JC, Hamze O, Fink JC, Klassen DK, Drachenberg RC, Wiland A, Wali R, Cangro CB, Schweitzer E, Bartlett ST, Weir MR: Clinical course of polyoma virus nephropathy in 67 renal transplant patients. J Am Soc Nephrol 13: 2145-51, 2002.
96. Brennan DC, Agha I, Bohl DL, Schnitzler MA, Hardinger KL, Lockwood M, Torrence S, Schuessler R, Roby T, Gaudreault-Keener M, Storch GA: Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. Am J Transplant 5: 582-94, 2005.
97. Awadalla Y, Randhawa P, Ruppert K, Zeevi A, Duquesnoy RJ: HLA mismatching increases the risk of BK virus nephropathy in renal transplant recipients. Am J Transplant 4: 1691-6, 2004.
98. Wali RK, Drachenberg C, Hirsch HH, Papadimitriou J, Nahar A, Mohanlal V, Brisco MA, Bartlett ST, Weir MR, Ramos E: BK virus-associated nephropathy in renal allograft recipients: rescue therapy by sirolimus-based immunosuppression. Transplantation 78: 1069-73, 2004.
99. Farasati NA, Shapiro R, Vats A, Randhawa P: Effect of leflunomide and cidofovir on replication of BK virus in an in vitro culture system. Transplantation 79: 116-8, 2005.
100. Kasiske BL, Snyder JJ, Gilbertson DT, Wang C: Cancer after kidney transplantation in the United States. Am J Transplant 4: 905-13, 2004.
101. Morath C, Mueller M, Goldschmidt H, Schwenger V, Opelz G, Zeier M: Malignancy in renal transplantation. J Am Soc Nephrol 15: 1582-8, 2004.
102. Koehl GE, Andrassy J, Guba M, Richter S, Kroemer A, Scherer MN, Steinbauer M, Graeb C, Schlitt HJ, Jauch KW, Geissler EK: Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice. Transplantation 77: 1319-26, 2004.
103. Campistol JM, Gutiérrez-Dalmau A, Torregrosa JV: Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma. Transplantation 77: 760-2, 2004.
104. Kasiske BL, Cangro CB, Hariharan S, Hricik DE, Kerman RH, Roth D, Rush DN, Vázquez MA, Weir MR; American Society of Transplantation: The evaluation of renal transplantation candidates: clinical practice guidelines. Am J Transplant 1 (Supl. 2): 3-95, 2001.